| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A comprehensive approach to reablement in dementia
|
Poulos, Christopher J.
|
|
2017
|
|
3 |
p. 450-458
9 p.
|
article
|
| 2 |
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
|
Samtani, Mahesh N.
|
|
2015
|
|
3 |
p. 157-169
13 p.
|
article
|
| 3 |
Alzheimer's disease drug development pipeline: 2017
|
Cummings, Jeffrey
|
|
2017
|
|
3 |
p. 367-384
18 p.
|
article
|
| 4 |
A multimodal approach to dementia prevention: A report from the Cambridge Institute of Public Health
|
Olanrewaju, Olawale
|
|
2015
|
|
3 |
p. 151-156
6 p.
|
article
|
| 5 |
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
|
Lues, Inge
|
|
2015
|
|
3 |
p. 182-195
14 p.
|
article
|
| 6 |
A randomized feasibility pilot trial of hearing treatment for reducing cognitive decline: Results from the Aging and Cognitive Health Evaluation in Elders Pilot Study
|
Deal, Jennifer A.
|
|
2017
|
|
3 |
p. 410-415
6 p.
|
article
|
| 7 |
B-vitamins are potentially a cost-effective population health strategy to tackle dementia: Too good to be true?
|
Tsiachristas, Apostolos
|
|
2016
|
|
3 |
p. 156-161
6 p.
|
article
|
| 8 |
Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project
|
Kunneman, Marleen
|
|
2017
|
|
3 |
p. 305-313
9 p.
|
article
|
| 9 |
Combined mnemonic strategy training and high-definition transcranial direct current stimulation for memory deficits in mild cognitive impairment
|
Hampstead, Benjamin M.
|
|
2017
|
|
3 |
p. 459-470
12 p.
|
article
|
| 10 |
Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
|
Peters, Oliver
|
|
2015
|
|
3 |
p. 198-204
7 p.
|
article
|
| 11 |
Delayed-start analysis for demonstrating disease modification of solanezumab
|
Wolters, Frank J.
|
|
2015
|
|
3 |
p. 196-197
2 p.
|
article
|
| 12 |
Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer's disease
|
Fischer, Corinne E.
|
|
2017
|
|
3 |
p. 385-392
8 p.
|
article
|
| 13 |
Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making
|
van der Flier, Wiesje M.
|
|
2017
|
|
3 |
p. 301-304
4 p.
|
article
|
| 14 |
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
|
Ferrero, James
|
|
2016
|
|
3 |
p. 169-176
8 p.
|
article
|
| 15 |
Insufficient evidence for vitamin E in Alzheimer's disease
|
Hermann, Dirk M.
|
|
2016
|
|
3 |
p. 199-201
3 p.
|
article
|
| 16 |
Lower brain and blood nutrient status in Alzheimer's disease: Results from meta-analyses
|
de Wilde, Martijn C.
|
|
2017
|
|
3 |
p. 416-431
16 p.
|
article
|
| 17 |
Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in community-dwelling older adults
|
Chuang, Yi-Fang
|
|
2017
|
|
3 |
p. 471-479
9 p.
|
article
|
| 18 |
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
|
Landen, Jaren W.
|
|
2017
|
|
3 |
p. 339-347
9 p.
|
article
|
| 19 |
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
|
Lanctôt, Krista L.
|
|
2017
|
|
3 |
p. 440-449
10 p.
|
article
|
| 20 |
NPT088 reduces both amyloid-β and tau pathologies in transgenic mice
|
Levenson, Jonathan M.
|
|
2016
|
|
3 |
p. 141-155
15 p.
|
article
|
| 21 |
Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project
|
Kunneman, Marleen
|
|
2017
|
|
3 |
p. 314-322
9 p.
|
article
|
| 22 |
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice
|
Majid, Tabassum
|
|
2015
|
|
3 |
p. 170-181
12 p.
|
article
|
| 23 |
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
|
Gold, Michael
|
|
2017
|
|
3 |
p. 402-409
8 p.
|
article
|
| 24 |
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
|
Landen, Jaren W.
|
|
2017
|
|
3 |
p. 393-401
9 p.
|
article
|
| 25 |
Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women
|
Wong, Rachel H.X.
|
|
2016
|
|
3 |
p. 162-168
7 p.
|
article
|
| 26 |
Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease
|
Huang, Zhiyue
|
|
2017
|
|
3 |
p. 360-366
7 p.
|
article
|
| 27 |
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
|
Timmers, Maarten
|
|
2016
|
|
3 |
p. 202-212
11 p.
|
article
|
| 28 |
Proof of concept demonstration of optimal composite MRI endpoints for clinical trials
|
Edland, Steven D.
|
|
2016
|
|
3 |
p. 177-181
5 p.
|
article
|
| 29 |
Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
|
Chen, Yun-Fei
|
|
2016
|
|
3 |
p. 192-198
7 p.
|
article
|
| 30 |
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health
|
Wheeler, Michael J.
|
|
2017
|
|
3 |
p. 291-300
10 p.
|
article
|
| 31 |
Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study
|
Mullan, Kathryn
|
|
2017
|
|
3 |
p. 432-439
8 p.
|
article
|
| 32 |
Technology for home dementia care: A prototype locating system put to the test
|
Megges, Herlind
|
|
2017
|
|
3 |
p. 332-338
7 p.
|
article
|
| 33 |
The BDNF Val66Met polymorphism moderates the effect of cognitive reserve on 36-month cognitive change in healthy older adults
|
Ward, David D.
|
|
2017
|
|
3 |
p. 323-331
9 p.
|
article
|
| 34 |
The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease
|
Burfeind, Kevin G.
|
|
2017
|
|
3 |
p. 348-359
12 p.
|
article
|
| 35 |
Vitamin E family: Role in the pathogenesis and treatment of Alzheimer's disease
|
Boccardi, Virginia
|
|
2016
|
|
3 |
p. 182-191
10 p.
|
article
|
Journal description